(respiratory syncytial virus vaccine, adjuvanted) GLAXOSMITHKLINE
AREXVY is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.
AREXVY is a suspension for injection supplied as a single-dose vial of lyophilised antigen component to be reconstituted with the accompanying vial of the adjuvant suspension component. A single dose after reconstitution is 0.5 mL.
